{"text": ["AbbVie", "shares", "jump", "2.2%", "on", "news", "of", "positive", "results", "in", "rheumatoid", "arthritis", "drug", "trial"], "created_at": "2018-04-09 12:54:22"}
{"text": ["AbbVie", "shares", "jump", "2.2%", "on", "news", "of", "positive", "results", "in", "rheumatoid", "arthritis", "drug", "trial"], "created_at": "2018-04-09 12:54:22"}
{"text": ["Upadacitinib", "Meets", "All", "Primary", "and", "Ranked", "Secondary", "Endpoints", "Including", "Superiority", "Versus", "Adalimumab", "in", "Phase", "3", "Study", "in", "Rheumatoid", "Arthritis"], "created_at": "2018-04-09 12:45:00"}
{"text": ["3", "Reasons", "This", "Clinical-Stage", "Biotech", "Is", "an", "Incredible", "Bargain"], "created_at": "2018-04-09 10:00:00"}
{"text": ["[$$]", "Merck", "eyes", "best", "day", "since", "2016,", "gains", "help", "fuel", "pharma", "rally"], "created_at": "2018-04-09 05:37:49"}
